BlueCrest Capital Management’s Frazier Lifesciences Acquisition Corporation Unit FLACU Stock Holding History

BlueCrest Capital Management’s Portfolio FLACU Stock Details FLACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$1M	–	542
2021 Q2	$1M	Hold	100,000	–	–	0.02%	378
2021 Q1	$1.02M	Hold	100,000	–	–	0.02%	532
2020 Q4	$1.04M	Buy	+100,000	New	+$1.04M	0.02%	288

Other funds holding FLACU

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

BlueCrest Capital Management's FLACU Position: Q3 2021 in Review

BlueCrest Capital Management sold out of Frazier Lifesciences Acquisition Corporation Unit (FLACU) in Q3 2021, closing a stake of 100,000 shares — an estimated $1M sold.

BlueCrest Capital Management first reported a position in FLACU in Q4 2020 and held it in 3 quarters. The position peaked at $1.04M in Q4 2020. 26 funds tracked by Wall St. Rank hold FLACU as of Q3 2021.

BlueCrest Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Unit position as of Q3 2021 after selling out during the quarter.
BlueCrest Capital Management sold 100,000 Frazier Lifesciences Acquisition Corporation Unit shares in Q3 2021, an estimated $1M.
BlueCrest Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Unit in Q4 2020 and held it in 3 quarters.
BlueCrest Capital Management's Frazier Lifesciences Acquisition Corporation Unit position peaked at $1.04M in Q4 2020.
26 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Unit as of Q3 2021.

Based on BlueCrest Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.